MTX-211 is primarily used in the field of oncology as a targeted therapeutic agent. It is designed to inhibit specific pathways involved in cancer cell proliferation and survival. The compound is often employed in preclinical research to study its efficacy against various tumor types, particularly those resistant to conventional treatments. MTX-211 is also explored in combination therapies to enhance the overall anti-cancer effect and reduce the likelihood of drug resistance. Its application extends to the development of personalized medicine, where it is tailored to target unique genetic mutations in individual patients. Additionally, MTX-211 is utilized in the validation of novel biomarkers, aiding in the identification of patients who are most likely to benefit from its use.